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Summary
Mucopolysaccharidosis (MPS) I is a lysosomal storage disease caused by a deficiency of
a-L-iduronidase (IDUA) (EC 3.2.1.76); enzyme replacement therapy is the conventional treatment
for this genetic disease. Arabidopsis cgl mutants are characterized by a deficiency of the activity
of N-acetylglucosaminyl transferase I (EC 2.4.1.101), the first enzyme in the pathway of hybrid
and complex N-glycan biosynthesis. To develop a seed-based platform for the production of
recombinant IDUA for potential treatment of MPS I, cgl mutant seeds were generated to express
human IDUA at high yields and to avoid maturation of the N-linked glycans on the recombinant
human enzyme. Enzyme kinetic data showed that cgl-IDUA has similar enzymatic properties to
the commercial recombinant IDUA derived from cultured Chinese hamster ovary (CHO) cells
(AldurazymeTM). The N-glycan profile showed that cgl-derived IDUA contained predominantly
high-mannose-type N-glycans (94.5%), and the residual complex/hybrid N-glycan-containing
enzyme was efficiently removed by an additional affinity chromatography step. Furthermore,
purified cgl-IDUA was amenable to sequential in vitro processing by soluble recombinant forms
of the two enzymes that mediate the addition of the mannose-6-phosphate (M6P) tag in
mammalian cells—UDP-GlcNAc:lysosomal enzyme Nacetylglucosamine (GlcNAc)1phos-
photransferase—and GlcNAc1phosphodiester aNacetylglucosaminidase (the ‘uncovering
enzyme’). Arabidopsis seeds provide an alternative system for producing recombinant lysosomal
enzymes for enzyme replacement therapy; the purified enzymes can be subjected to
downstream processing to create the M6P, a recognition marker essential for efficient receptor-
mediated uptake into lysosomes of human cells.
Introduction
Lysosomal storage diseases (LSDs) collectively represent over 70
inherited metabolic disorders. The underlying etiology of many
LSDs involves a deficiency of a single acid hydrolase. Enzyme
replacement therapy (ERT) is the conventional treatment. While
some enzyme replacement therapeutics are in the ‘pipeline’ and
are under different phases of clinical evaluation (van Gelder et al.,
2012), to date, these therapeutics have been registered for only a
few of the LSDs: Gaucher disease, Fabry disease, Pompe disease
and mucopolysaccharidoses (MPS I, II, and VI). ERT is a process
that takes advantage of plasma membrane receptor uptake to
deliver recombinant enzyme into a patient’s cells following
intravenous infusion of the replacement enzyme (Neufeld,
2011). Mucopolysaccharidosis I (MPS I) disease is an LSD
characterized by the deficiency of a-L-iduronidase (IDUA), an
enzyme involved in the stepwise degradation of the glycosami-
noglycans heparan sulphate and dermatan sulphate. Because of
the widespread distribution of these glycosaminoglycans in
tissues and organs, severely affected humans with no residual
a-L-iduronidase typically die in early childhood due to profound
skeletal, cardiac and neurological disturbances (Clarke, 2008).
The current approved ERT for MPS I (AldurazymeTM or Laroni-
dase), based on the recombinant IDUA from Chinese hamster
ovary (CHO) cells, is prohibitively expensive, costing approxi-
mately US$450 000 per year for an average 12-year-old child. As
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costs are calculated on the basis of the weight of an individual,
treatments for teenagers and adults are even higher.
Plant-based systems offer an alternative protein production
platform that could reduce the costs associated with these
therapies. An enzyme therapeutic for Gaucher disease generated
by a plant platform (carrot suspension cell cultures) was approved
by the US Food and Drug Administration in 2012 (Maxmen,
2012; Shaaltiel et al., 2007) and represents the first plant-based
recombinant therapeutic approved for parenteral administration.
Some of the advantages of plant expression systems include the
following: relatively low production costs due to an ability to
rapidly accumulate biomass and a lack of susceptibility to
contamination by human pathogens as can occur in mammalian
expression systems, such as CHO cells or human fibroblasts.
Seeds, as natural depots for stable accumulation of proteins,
offer additional advantages as a ‘host’ platform: recombinant
proteins are usually stable in the mature seeds placed in
conventional (cool, dry) storage conditions, and the seeds remain
viable for several years. Thus, seeds serve as a stable repository of
the therapeutic protein providing the convenient option of
temporally separating the production of the recombinant protein
from its purification and downstream processing (Kermode,
2012).
Nonetheless, the use of plants as platforms for the production
of recombinant lysosomal enzymes suitable for ERT poses at least
three technical challenges. First, sufficient yields of the recombi-
nant enzyme must be obtained to render economic viability to the
production platform. Second, a nonimmunogenic and active
recombinant protein must be generated. While the initial steps of
protein N-glycosylation and subsequent N-glycan trimming that
are essential for proper protein folding are common to plant and
animal cells, differences occur in N-glycan maturation as proteins
transit through the distal compartments of the Golgi complex
(medial-, trans- and trans-Golgi networks). In these compart-
ments, enzymes convert the high-mannose-type N-glycans of
proteins to complex N-glycans by a series of sequential reactions
that rely on the accessibility of the glycan chain(s) to the Golgi
processing machinery (Gomord et al., 2010; Kermode, 1996). In
mammalian cells, core a1,6 fucose residues and terminal sialic
acid residues are commonly added, whereas bisecting b1,2 xylose
and core a1,3 fucose residues are assembled onto the trimmed
N-glycans of plant-synthesized proteins. The presence of b1,2
xylose and/or a1,3 fucose residues on plant-produced pharma-
ceuticals can render the product immunogenic, which is a
concern for any therapeutic destined for parenteral administra-
tion (reviewed in Gomord et al., 2010).
Third, there are challenges associated with generating a
therapeutically efficacious product; the parenterally administered
recombinant enzyme must have suitable targeting signals for
endocytosis into patient cells and for intracellular delivery to the
lysosome. For most lysosomal enzymes (e.g. a-L-iduronidase and
several others), this requires the cellular recognition marker,
mannose-6-phosphate (M6P), on the replacement protein.
In mammalian cells, Golgi-specific enzymatic processing medi-
ates M6P elaboration, a process involving the modification of
select terminal mannose residues of some of the N-glycans of
lysosomal hydrolases. Thus, lysosomal hydrolases typically possess
various N-glycans, namely those of the high-mannose-, complex-
or M6P-terminated types. The M6P recognition motif normally
mediates the targeting of soluble lysosomal enzymes from the
trans-Golgi network to the lysosome, but can also mediate the
internalization of inappropriately secreted lysosomal enzymes via
the so-called ‘salvage’ pathway. ERT for LSDs largely exploits this
endogenous ‘salvage’ (uptake) pathway of human cells, which is
effected by cell surface endocytic receptors, such as the M6P
receptors (reviewed in Gary-Bobo et al., 2007). ‘Retrieval’ or
sequestration of an extracellular (e.g. recombinant) lysosomal
enzyme due to recognition of its M6P marker can result in delivery
to the lysosome by receptor-mediated endocytosis via early and
late endosomes, enabling the correction of an enzyme deficiency.
Thus, a key challenge lies in the fact that plant cells do not have
the endogenous machinery to create the M6P tag on a
recombinant protein; a viable option is to create this on the
purified protein in vitro, that is, as part of downstream processing.
In this study, we address the three challenges associated with
plant-based platforms for the production of recombinant lyso-
somal enzymes destined for ERT, focussing on human IDUA.
Through selection and inbreeding, we identified an Arabidopsis
thaliana (Arabidopsis) seed line that significantly exceeds our
previously reported yields of recombinant human IDUA by at least
threefold (Downing et al., 2006, 2007); in this line, IDUA
represented 5.7% of the total soluble seed protein (TSP), and
the yield was stable through T3 and T4 generations. This
Arabidopsis seed line represents a mutant background (the
complex glycan-deficient or cgl1 C5 mutant), in which N-glycan
maturation is avoided due to a deficiency of the Golgi enzyme
N-acetylglucosamine transferase I (GnT I); importantly, we show
by graphitized carbon liquid chromatography–tandem mass
spectrometry that high-mannose-type N-glycans accounted for
94.5% of the N-glycans on the cgl-IDUA. Kinetic parameters of
the cgl-derived IDUA were comparable with those of Aldura-
zymeTM (the commercial CHO cell–derived IDUA); we further
demonstrate that the plant recombinant enzyme was amenable
to in vitro downstream processing using two recombinant soluble
human enzymes: GlcNAc-1-phosphotransferase and the ‘uncov-
ering enzyme’, to generate the M6P recognition motif.
Our results show that Arabidopsis cgl seeds provide a viable
production system for recombinant human IDUA, generating
enzyme that is potentially suitable for treating patients with MPS I.
Results
Arabidopsis cgl seeds accumulate high levels of active
a-L-iduronidase
Previously, we reported that using the promoter and other
regulatory sequences of the Phaseolus vulgaris arcelin 5-I gene,
three transgenic Arabidopsis cgl lines with exceptional activities
were identified; these possessed IDUA activities of 820  63,
745  75 and 423  19 units/mg TSP (Downing et al., 2007;
lines A5.5, A4.7 and A6.3, respectively). The highest yielding line
accumulated IDUA to approximately 18 lg IDUA/mg TSP (Down-
ing et al., 2007). Here we further improved the yield by selfing of
plants and by further selection. T2 seeds from the three lines were
germinated on selection media (25 mg/L kanamycin in half-
strength Murashige and Skoog [MS] medium). Ten to 15
transgenic seedlings from each line were grown to maturity and
selfed to obtain T3 seeds. Protein was extracted from each seed
stock, and the expression levels were determined by activity
assays and Western blot analyses. Ten transgenic seedlings from
each of the highest expressers were selfed to generate T4 seeds.
Interestingly, the highest expressing line of T3 seeds accumulated
IDUA at 11.2% TSP (Table 1 and Figure 1a, lane 2), but the
expression level of the subsequent generation (T4) decreased
significantly (Table 1). Although we have not determined the
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zygosity of the transgene, the highest yielding line (with relatively
stable trans-generation expression) accumulated IDUA at 5.7%
TSP (Table 1).
Cgl-derived IDUA contains predominantly
high-mannose-type N-glycans
There are six consensus sites for N-linked glycosylation on
a-L-iduronidase (Asn-X-Ser/Thr); all sites are utilized in human
cells (Kakkis, 2005). In CHO cells hosting production of the
recombinant protein, the enzyme is secreted, and all six glyco-
sylation sites are used, but the N-linked glycans themselves
display high intrasite heterogeneity (Zhao et al., 1997). Some of
the N-linked glycans of the mature enzyme remain in a high-
mannose form (Asn 372; Asn 415 is mixed high mannose and
complex); at least two of the sites are modified to complex forms
(Asn 110 and Asn 190); two carry M6P tags for receptor-
mediated uptake/lysosome delivery (Asn 336 and Asn 451) (Zhao
et al., 1997).
In the Arabidopsis cgl mutant, the N-glycan status of the
recombinant protein appears to depend on both the target
protein and the plant tissues that ‘host’ its expression (see
Discussion). As shown in Figure 2 and Table 2, 94.5% of the
N-glycan structures detected in the purified cgl-IDUA (Figure 1b)
by carbon LC MS/MS were of the oligomannosidic type contain-
ing 1–7 hexose residues in addition to the pentasaccharide
N-glycan core. Among these structures, a Man5 structure (i.e.
Man5GlcNAc2) was the most abundant (50.6%). Complex and
hybrid structures containing core a 1,3 fucose and/or b 1,2 linked
xylose accounted for 5.5% of the total structures detected
(Table 2). One glycopeptide could be identified from the cgl-IDUA
samples, indicating incomplete digestion with PNGase A. Never-
theless, this allowed the identification of high-mannose-type
N-glycosylation at site Asn 372 (Figure 3).
The purified cgl-IDUA sample was subjected to further affinity
chromatography with anti-horseradish peroxidase (HRP) antibod-
ies to determine whether the small amounts of recombinant
enzyme containing plant complex and hybrid N-glycans (approx-
imately 5.5%) could be efficiently removed. As shown in Figure 4
and Table 3, Man5 accounted for 93.8% of the N-glycans, while
Man6–Man8 accounted for 6.2% of the N-glycans. No plant
complex or hybrid N-glycans were detected. Thus, the anti-HRP
chromatography step gave rise to a single dominant N-glycan
structure of IDUA.
Cgl-IDUA exhibits kinetic parameters that are
comparable with the commercial enzyme
IDUA was purified to homogeneity from T4 seeds (line A4.7) by
sequential use of ConA-Sepharose chromatography and anti-
IDUA affinity chromatography as described in He et al. (2012c)
(Figure 1b). Using 4-MUI as substrate, the cgl-IDUA exhibited a
Km of 44 lM and a Vmax of 5.6 lM/min/mg (Figure 5). The values
are comparable with those of IDUA produced in CHO cell cultures
(AldurazymeTM), for which the Km is 24 lM and the Vmax is
3.9 lM/min/mg (He et al., 2012c).
Cgl-IDUA is amenable to sequential in vitro processing
to add the M6P recognition marker
Most lysosomal enzymes including a-L-iduronidase require a M6P
tag for efficient uptake and lysosomal delivery in human cells. In
mammalian cells, the M6P tag is generated by the sequential
action of two enzymes: UDP-GlcNAc:lysosomal enzyme
Table 1 Accumulation of IDUA (as% total soluble seed protein (TSP) or lg/mg seeds) in transgenic Arabidopsis seed lines
Line
T2 T3 (SD) T4 (SD)
%TSP lg/mg %TSP lg/mg %TSP lg/mg
A4.7 1.7 2.7 7.2  0.6 9.8  0.57 5.7  0.4 8.0  0.8
A5.5 1.8 3.0 11.2  2.7 16.3  2.1 2.5  0.14 4.0  0.55
A6.3 0.94 1.6 2.6  0.23 4.3  0.40 1.6  0.08 2.3  0.18
TSP, total soluble protein; SD, standard deviation of three replicates. For T3 seeds, only the highest line among the 15 siblings is presented; for T4 seeds, the
accumulation levels were measured in a seed stock pool made up of seeds from 10–15 transgenic plants.
(a)
(b)
Figure 1 a-L-Iduronidase (IDUA) produced in Arabidopsis cgl seeds.
(a) Western blot analysis of IDUA produced in T3 seeds of 3 high-
expressing lines. Lanes 1–4: 0.4 lg of total soluble protein was loaded
from the crude extracts of cgl untransformed seeds (lane 1) and from
seeds of transformed lines A5.5, A4.7 and A6.3, respectively (lanes 2–4).
Lanes 5–6 show 20 ng and 50 ng of purified cgl-IDUA (from line A4.7),
respectively. (b) Five micrograms of affinity-purified cgl-IDUA (line A4.7)
was loaded on a 10% gel, and after SDS-PAGE, the gel was stained with
Coomassie Brilliant Blue and destained. Molecular weights of the
prestained protein markers are indicated on the left.
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N-acetylglucosamine-1-phosphotransferase (also known as
GlcNAc-1-phosphotransferase) and N-acetylglucosamine 1-phos-
phodiester a-N-acetylglucosaminidase (the uncovering enzyme).
The endogenous mammalian GlcNAc-1-phosphotransferase is a
heterohexamer comprised of three subunits (a2b2c2) and is
localized within the cis-Golgi (Bao et al., 1996). GlcNAc-
1-phosphotransferase catalyses the transfer of GlcNAc-P from
UDP-GlcNAc to C6 of select mannoses of the lysosomal enzyme’s
high-mannose-type oligosaccharides. The a/b subunits contain
the catalytic function of the phosphotransferase and further are
responsible for the specificity of the reaction by recognition of a
conformation-dependent determinant of the lysosomal enzyme
(Kudo et al., 2005; Lee et al., 2007; Qian et al., 2010). The
human uncovering enzyme is synthesized as a proenzyme that is
Table 2 N-glycans identified in cgl-IDUA
Abbreviation Structures Rel. amount (%) Hex HexNAc Fuc Xyl
Complex and hybrid type
structures
MMX 1.3 3 2 1
MMXF 3.8 3 2 1 1
Man5F 0.4 5 2 1
Oligomannosidic structures Man4 3.7 4 2
Man5 50.6 5 2
Man6 3.6 6 2
Man7 9.0 7 2
Man8 13.8 8 2
Man9 11.0 9 2
Man9 + Hex 2.8 10 2
Figure 2 N-glycans of cgl-a-L-iduronidase
(IDUA). Summed mass spectra of N-glycans from
cgl-IDUA. Signals were identified as [M–H]
signals unless stated otherwise. Oligomannosidic
structures comprised more than 90% of the
structures identified (see also Table 2).
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activated by the endoprotease furin in the trans-Golgi network
(Do et al., 2002). This enzyme excises the terminal GlcNAc,
exposing the M6P recognition marker on lysosomal hydrolases.
Both the GlcNAc-1-phosphotransferase (as a a2b2 heterotetr-
amer) and the uncovering enzyme have been generated as
soluble forms (Do et al., 2002; Kudo and Canfield, 2006) and so
can be used to conduct the in vitro phosphorylation of purified
recombinant lysosomal enzymes.
We first investigated whether the N-glycan terminal mannose
residues of the cgl-IDUA could be modified in vitro using
recombinant soluble GlcNAc-1-phosphotransferase (a2b2). Equal
amounts of the phosphotransferase (1.5 lg) were incubated with
increasing concentrations of cgl-IDUA in the presence of 75 lM
UDP-[3H]GlcNAc for 1 h, and transfer of [3H]GlcNAc-P to
cgl-IDUA was measured. Figure 6 illustrates the activity of the
GlcNAc-1-phosphotransferase towards cgl-IDUA based on the
data of one representative experiment. Kinetic parameters were
determined using the double-reciprocal plot from 3 experiments.
Cgl-IDUA exhibited a Km of 4.3 lM and a kcat of 0.10 min
1 (Vmax
of 21.7 pmol/h/lg).
Table 3 N-glycans identified in cgl-IDUA after anti-HRP affinity
chromatography
N-glycan type Det. m/z Structures IDUA
High-mannose type [M + Na]+ Rel. int. [%]
Man5 1257.507 93.83
Man6 1419.556 1.59
Man7 1581.598 2.57
Man8 1743.722 1.65
Man9 1905.742 0.36
Figure 4 N-glycans on cgl-IDUA after anti-HRP affinity chromatography identified by MALDI-TOF MS. Glycan cartoons are according to the
recommendations of the consortium of functional glycomics (www.functionalglycomics.org).
Figure 3 High-mannose type N-glycan at site Asn 372 on recombinant cgl-IDUA protein (glycopeptide 369–383).
Figure 5 Michaelis–Menten plot for cgl-IDUA. Assays were performed in
triplicate. The inset on the right is the Lineweaver–Burk plot.
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Next we examined the efficiency by which the uncovering
enzyme cleaved GlcNAc from the phosphorylated cgl-IDUA by
monitoring the concentrations of free [3H]GlcNAc over a time
course. The amount of liberated [3H]-GlcNAc increased with time
(Figure 7), suggesting that the covering GlcNAc of the phos-
phorylated IDUA can be readily removed by the uncovering
enzyme to expose the M6P tag.
Discussion
In this study, we sought to address the technical challenges of
plant-based production of recombinant enzymes as replacement
therapeutics for patients with lysosomal storage disease (LSD). To
recap, these challenges pertain to the development of econom-
ically viable production systems that generate non-immunogenic
and functional therapeutics (see Introduction).
High levels of active a-L-iduronidase (IDUA) are
produced in Arabidopsis cgl seeds
Arabidopsis seeds have attracted considerable attention as a
platform to produce recombinant proteins. In this regard,
Arabidopsis has several advantages: its life cycle is short, it can
be readily grown in a controlled environment, and compared with
several other seed-based systems, it is not a food crop that
consequently reduces the regulatory issues surrounding its use as
a source of recombinant proteins. In addition, exceptionally high
levels of functional recombinant proteins can be accumulated in
Arabidopsis seeds. For example, a single-chain variable fragment
(scFv) antibody is accumulated to 74 lg/mg of TSP in homozy-
gous Arabidopsis seeds (De Jaeger et al., 2002); likewise, the
maximal accumulation of antihepatitis A virus antibodies reaches
9.8 lg/mg in dry seeds (Loos et al., 2011). In our study, we
obtained accumulation levels of IDUA that significantly exceeded
our previous reports (Downing et al., 2006, 2007), reaching
57 lg/mg TSP (corresponding to 8.0 lg/mg dry seeds) in T4
transgenic Arabidopsis seeds. At this level of expression, one
milligram of purified IDUA can be obtained from <1 g of seeds
using the chromatographic methods of the present study.
One might be able to apply the lessons learned from
Arabidopsis to production of recombinant proteins in a larger
seed system, possibly in seeds of a cereal or another dicot.
However, efforts to completely knock-out GnT I expression in
hosts other than Arabidopsis, for example in dicots such as potato
and tobacco, lead to a reduction in complex N-glycans on
endogenous plant proteins (Wenderoth and von Schaewen,
2000), but the extent of silencing would not adequately control
the N-glycan maturation of a recombinant therapeutic protein. In
addition, the yield of IDUA in the stable high-expressing cgl
Arabidopsis line (A4.7) of the present study is approximately 47
times higher than that of transgenic maize seeds (1.2 lg/mg TSP)
(He et al., 2012c). The amount of IDUA accumulation in cgl seeds
also exceeds other seed-based systems; it is about 25–30 times
higher than the IDUA levels accumulated by seeds of transgenic
tobacco (2.2 lg/mg TSP) and Brassica napus (1.9 lg/mg TSP)
using the same (arcelin gene) regulatory sequences to drive the
human gene expression (Galpin et al., 2010).
The development of automated sowing and harvesting of pilled
Arabidopsis seeds for bulk production of biomass (Loos et al.,
2011) represents another advantage for the use of Arabidopsis as a
host production system.With the expression level of cgl-IDUA at 7–
9 lg/mg dry seeds (line A 4.7), the estimated annual production
yields of IDUA per square metre (sqm) would range from 1.2 g to
1.6 g (based on 200 mg seeds per plant; 300 plants per sqm; 3
generations per year). A single patient of 40 kg (upper estimate for
body weight of 12-year-old patient) (Pastores et al., 2007) would
annually require approximately 1.2 g of purified IDUA (based on
weekly infusions of 0.58 mg/kg of body weight as recommended
for Aldurazyme; http://www.aldurazyme.com/global/az_us_h-
ome.asp). With an estimated worldwide incidence of MPS I as 1
in 100 000 live births (Muenzer et al., 2009) (or potentially
approximately 70 000 patients globally), the generation of suffi-
cient cgl-IDUA to meet the potential annual market needs would
require approximately 140 000 sqm of growth area (approxi-
mately 34.6 acres), taking into account the purification yields. Yet
this calculation is based on many assumptions, and the true
feasibility of using Arabidopsis seeds to produce enzyme thera-
peutics for patients with LSD will rely upon numerous factors, not
the least of which is the associated costs and efficiency of
downstream processing (see subsequent discussion).
The maturation of the N-glycans of recombinant IDUA is
avoided in Arabidopsis cgl seeds
Aside from achieving sufficient yields of a therapeutic recombi-
nant protein, plant-specific N-glycan maturation limits the use of
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plant-based systems as factories to produce recombinant phar-
maceutical proteins; the presence of xylose and fucose residues
on ‘matured’ N-glycans of the protein may render the product
immunogenic if administered parenterally (see Introduction). The
human IDUA enzyme has six consensus signals for N-linked
glycosylation in the ER; these are all utilized in human cells in
which the enzyme is targeted to the lysosome via the Golgi
complex. In CHO cells hosting production of the recombinant
protein, the enzyme is secreted, and again all six sites are used,
but the N-linked glycans are heterogeneous (Zhao et al., 1997)
(see Results). To reduce or eliminate plant-specific N-glycan
maturation, various strategies have been implemented such as a
targeted localization of recombinant proteins within the ER or
ER-derived compartments, down-regulating glycosyltransferases
(e.g. N-acetylglucosamine transferase I, a1,3 fucosyltransferases
and b1,2 xylosyltransferase) by RNAi technology or by the use
of mutants, and expressing human glycosyltransferases (e.g.
b1,4-galactosyltransferase) (reviewed in Gomord et al., 2010;
Kermode, 2012; He et al., 2012c). Towards developing various
plant-based platforms for the production of recombinant lyso-
somal enzymes for use in ERT, we have used some of the
strategies applied to recombinant human IDUA and/or glucocer-
ebrosidase. Two strategies for ER retention of recombinant IDUA
have included KDEL tagging (He et al., 2012b) and exploitation of
a unique mRNA-targeting mechanism in maize seeds, a process
which effectively localizes recombinant IDUA to ER-derived
protein bodies (He et al., 2012c). Only this latter strategy is
effective in controlling the N-glycan maturation of IDUA and
further has the advantage of yielding a native enzyme with no
additional (i.e. foreign) amino acid sequences (He et al., 2012c).
For example, the KDEL-tagged IDUA of Arabidopsis seeds
contains 88% complex/hybrid N-glycans (He et al., 2012b), while
the mRNA-mediated targeting of IDUA to ER-derived protein
bodies in maize seeds generates only 8.2% hybrid/complex
N-glycans (He et al., 2012c).
As shown in the present study (and in He et al., 2012a for
glucocerebrosidase), use of seeds of the Arabidopsis cgl mutant is
also a viable means to control the N-glycan maturation status of
recombinant lysosomal enzymes. The cgl mutant is defective in
the gene encoding the Golgi enzyme N-acetylglucosamine
transferase I (GnT I) (EC 2.4.1.101) (von Schaewen et al., 1993;
Strasser et al., 2005). GnT I transfers a GlcNAc residue from UDP-
GlcNAc to the acceptor substrate Man5GlcNAc2 to produce
GlcNAcMan5GlcNAc2, which is essential for the subsequent
action of a1,3 fucosyltransferases and b1,2 xylosyltransferase to
add their respective (plant-specific) sugar residues. The deficiency
of GnT I activity in the cgl mutant leads to a vast reduction in
complex and hybrid N-glycans on the plant (endogenous) proteins
(von Schaewen et al., 1993), although the effectiveness of this
strategy for manipulating the N-glycan status of recombinant
proteins appears to be protein specific (Kermode, 2012) and is
considerably more effective for recombinant human IDUA (this
study) than for recombinant human glucocerebrosidase (He
et al., 2012a).
Earlier reports of the cgl mutant showed an absence of
complex N-glycans on endogenous glycoproteins of plant leaf
extracts or callus extracts, with the predominant type of N-glycan
being Man5 (Man5GlcNAc2) (von Schaewen et al., 1993; Strasser
et al., 2004, 2005). Later, Frank et al. (2008) demonstrated the
conditional nature of this particular cgl mutant (cgl1 C5), for
which a point mutation leading to a destabilized GnT I enzyme
accounts for the phenotype (Strasser et al., 2005). For example,
tunicamycin treatment relieves the ‘folding block’ for the mutant
GnT I protein, permitting its transit to the Golgi complex. More
recently, our results of the N-glycan profiles for cgl1 C5 mutant-
derived recombinant lysosomal enzymes (this study and He et al.,
2012a,b) suggest that there is a partial restoration of GnT I
activity during seed development in this particular mutant.
Despite this, we show here that cgl-derived IDUA contained
predominantly high-mannose-type N-glycans (94.5%), with a
Man5 structure accounting for 50.6%. The small amount of
recombinant IDUA containing complex/hybrid N-glycans (5.5%)
was efficiently removed by an additional purification step—an
affinity chromatography using conjugated antihorseradish perox-
idase (HRP) antibodies. Interestingly, this led to a single dominant
N-glycan of IDUA (Man5: 93.8%) without detectable plant-
specific complex/hybrid N-glycans (i.e. those containing xylose/
fucose residues). Thus, from the point of view of controlling
N-glycan maturation of IDUA, the strategy of hosting expression
in the cgl1 seed background is very efficient, and the enzyme is
stable as a secreted protein.
Incomplete digestion of cgl-IDUA by PNGase A allowed the
structural analysis of an N-glycan at one consensus N-glycosyla-
tion site (Asn 372); this site possessed a high-mannose-type
N-glycan (Man 6–9). The high-mannose-type N-glycan at Asn 372
is consistently generated on recombinant IDUA regardless of the
host production system; it occurs in both Arabidopsis seeds (this
study and He et al., 2012b for IDUA-KDEL) and in mammalian
(CHO) cell cultures (Zhao et al., 1997). This suggests that within
the folded mature IDUA protein, the N-glycan at this site is
protected from ‘maturation’ by its inaccessibility to the modifying
enzymes of the Golgi complex in both plant and mammalian host
cells (i.e. the a1,3 fucosyltransferases and b1,2 xylosyltransferase
in the former, and the b1,4 galactosyltransferase and sialyltrans-
ferase enzymes in the latter).
Cgl-IDUA can be processed in vitro to generate the M6P
recognition marker required for lysosomal targeting in
human cells
Another challenge associated with plant-based systems for
production of LSD enzyme therapeutics is the lack of the
endogenous machinery in plant cells required to generate the
M6P recognition marker; this tag is ultimately of importance for
efficacy of most LSD enzyme therapeutics as their uptake and
subsequent lysosomal targeting in human cells occur largely via
M6P-receptor-mediated transport systems. The formation of the
M6P recognition marker in mammalian cells is catalysed by the
sequential action of two enzymes: GlcNAc-1-phosphotransferase
and the ‘uncovering’ enzyme. Of the two mammalian/human
enzymes involved in creating the M6P tag, the first—the GlcNAc-
1-phosphotransferase—is essential for lysosomal trafficking of
most lysosomal enzymes as mutations in the gene can cause
mucolipidosis II, mucolipidosis IIIA or mucolipidosis IIIC (Kudo
et al., 2006). No lethal disease has been directly linked with a
deficiency of the uncovering enzyme perhaps because the cation-
independent M6P receptors can also recognize the disaccharide
Man-P-GlcNAc (Olson et al., 2010), although a link between
mutations in the gene encoding the uncovering enzyme and
persistent stuttering has been reported (Lee et al., 2011). CHO
cell–produced IDUA typically possesses two M6P tags (at Asn336
and Asn451), which are primarily of the biphosphorylated variety:
P2Man7GlcNAc2 (Zhao et al., 1997).
In the present study, we tested the efficacy of an in vitro
process to achieve the addition of M6P on cgl-IDUA. Kinetic
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parameters of the soluble GlcNAc-1-phosphotransferase with
cgl-IDUA as a substrate were determined (Km of 4.3 lM and a kcat
of 0.10 min1). These values are comparable with those of CHO-
IDUA treated with alkaline phosphatase (He et al., 2012c). The
cgl-IDUA was amenable to the addition of GlcNAc-P by the
soluble recombinant phosphotransferase; through monitoring of
the release of [3H]-GlcNAc, we further showed that the covering
GlcNAc of the phosphorylated IDUA was readily removed by the
uncovering enzyme to expose the M6P tag.
Despite this advance in the downstream processing of a plant-
made recombinant lysosomal enzyme, the efficiency of the first
step of the in vitro process (that mediated by the soluble GlcNAc-
1-phosphotransferase) clearly needs to be improved. This could
be achieved either by modifying the in vitro process itself, or,
more readily, by modifying the characteristics of the plant
recombinant lysosomal enzyme, such as optimizing the number
of mannose residues that represent the predominant species of
high-mannose-type N-glycans. The phosphotransferases of rat
liver and simple eukaryotes (Acanthamoeba castellani, and
Dictyostelium discoideum) seem to require N-glycans containing
Man6 and higher, partly because they contain the required a1,2-
linked mannose residues (Couso et al., 1986; Ketcham and
Kornfeld, 1992). No phosphorylation of N-oligosaccharides
comprised of Man5 is detected, at least on the target hydrolase
that was studied – uteroferrin (Couso et al., 1986; Ketcham and
Kornfeld, 1992). The kcat value of the phosphotransferase for the
plant recombinant IDUA as substrate is about 18 times less than
that for the mammalian lysosomal protease cathepsin D (Qian
et al., 2010). The lower kcat value may suggest that, as
compared to cathepsin D, the N-glycans on the cgl-IDUA are
less efficiently phosphorylated by the soluble phosphotransfer-
ase. Yet the Km value suggests that the phosphotransferase
binds very effectively to the plant IDUA, and part of the
efficiency of the phosphotransferase is indeed reliant upon its
affinity for the target hydrolase (Qian et al., 2010). The extent of
phosphorylation of a glycoprotein by the phosphotransferase is
influenced by the position of the N-glycans relative to the
binding site for the phosphotransferase; this modifying enzyme
functions best on target lysosomal hydrolases with Man6–
Man8 N-glycans (Varki and Kornfeld, 1980). This factor may
indeed have influenced the extent of GlcNAc-P transfer in the
present case as the majority of the N-glycans of cgl-IDUA are
oligomannosidic containing Man5 (Man5 structures account for
50.6%), although approximately 26% are Man 6–8. Perhaps also
notable, despite the N-glycan at Asn372 of cgl-IDUA being of
favourable mannose number, this site on IDUA appears to be
protected from accessibility to the phosphotransferase, at least in
situ (Zhao et al., 1997).
In summary, we have addressed some of the technical
challenges of plant-based production of recombinant enzymes
for treatment of lysosomal storage diseases. We are now
conducting work to improve the efficiency of the in vitro
phosphorylation of recombinant IDUA in part through the
manipulation of the length of the high-mannose-type N-glycans
on this human enzyme and by other means.
Experimental procedures
Protein extraction and a-L-iduronidase activity assays on
transgenic cgl lines
Procedures for extraction of total soluble protein from seeds and
analyses of a-L-iduronidase (IDUA) activities were as described in
the study of Downing et al. (2006). Protein amounts were
determined using the Bio-Rad DC protein assay kit (Bio-Rad
Laboratories, Mississauga, Ontario, Canada) using bovine serum
albumin as the standard. The IDUA activities of cgl seed extracts
were determined at 37 °C and pH 4.5 using 2 mM 4-methylum-
belliferyl-a-L-iduronide (4-MUI) as the substrate. Reactions were
performed in a total volume of 15 lL, in 0.1 M dimethylglutarate
buffer, pH 4.5, 2 mM sodiummetabisulfite and 0.7%bovine serum
albumin. Reactions were stopped by the addition of 0.1 M glycine
buffer, pH 10.7. Fluorescence of the reaction product, 4-methyl-
umbelliferone (4-MU), was determined (kex = 365 nm,
kem = 460 nm). The activities were expressed as units/mg TSP,
where one unit is defined as 1 nmol 4-MU/min.
Affinity purification of cgl-derived a-L-iduronidase
Affinity purification of cgl-IDUA using concanavalin A-Sepharose
(ConA-Sepharose) chromatography and affinity chromatography
with a monoclonal antibody against IDUA was carried out
essentially as described previously (He et al., 2012c).
N-glycan profiles of cgl-derived IDUA
Purified IDUA (approximately 4 lg) was resolved by 10%
SDS-PAGE, and the IDUA protein bands recovered from the gel.
N-glycans were released from tryptic peptides obtained after in-gel
digestion, and graphitized carbon liquid chromatography MS/MS
(carbon LC MS/MS) was used for N-glycan analysis as outlined in
He et al. (2012c).
Anti-horseradish peroxidase affinity chromatography
for removal of small amounts of a-L-iduronidase
containing plant complex/hybrid N-glycans
Approximately 5% of the IDUA derived from cgl seeds contained
matured (complex or hybrid) N-glycans, that is, N-glycans with
xyloseand/or fucose.This small fractionof the IDUAwasremovedby
passing the purified IDUA (a single band on SDS-PAGE) through an
anti-horseradish peroxidase affinity column (recycling overnight at
4 °C) according to the method described by He et al. (2012c). The
column specifically binds to xylose and/or fucose residues (Wilson
et al., 1998), allowing for the removal of any IDUAcontaining these
sugars from the sample. The resultant IDUA was resolved on 10%
SDS-PAGE, and its N-glycan composition was determined by
MALDI-TOF MS analyses as described in He et al. (2012b).
Determination of kinetics of cgl-derived IDUA
The Michaelis–Menten kinetic parameters of 4-MUI cleavage by
cgl-IDUA were determined using IDUA enzyme purified by ConA-
Sepharose and anti-IDUA affinity chromatography. The fluoro-
metric activity assay outlined above was performed using a total
volume of 100 lL. The substrate (4-MUI) was used at concen-
trations of 1 to 800 lM to ensure the coverage of a sufficient
range encompassing the Km. Reactions were started upon the
addition of enzyme (0.035 lg per assay) and allowed to proceed
for 10 min, over which time it had been determined that the rate
of the reaction remained linear. Reactions were stopped by the
addition of 0.1 M glycine buffer, pH 10.7. The amount of 4-MU
produced at each substrate concentration was determined by
measuring the fluorescence and converting the value into a
concentration using a standard curve that was prepared using
4-MU concentrations between 0.1 and 125 lM. Rates of catalysis
were determined by dividing the reaction time and concentration
of the enzyme and fit to a Michaelis–Menten curve using GRAFIT.
All measurements were made in triplicate.
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Modification of cgl-IDUA by a recombinant soluble a2b2
GlcNAc-1-phosphotransferase
For in vitro phosphorylation of cgl-IDUA that had been purified by
sequential ConA-Sepharose and anti-IDUA affinity chromatogra-
phy, the recombinant a2b2 GlcNAc-1-phosphotransferase
(1.5 lg) was added to the reaction mixtures containing various
concentrations of cgl-derived IDUA in 50 mM Tris–HCl, pH 7.4,
10 mM MgCl2, 10 mM MnCl2, 75 lM UDP-[
3H]GlcNAc (1 lCi) and
2 mg/mL bovine serum albumin in a final volume of 50 lL. The
assay was carried out as described by Qian et al. (2010). Apparent
Km and kcat values were generated from double-reciprocal plots
using a least-square approximation for the best fit line. The values
were the average of three separate determinations.
Removal of GlcNAc by the uncovering enzyme
The uncovering enzyme activity assay was performed according
to Mullis and Ketcham (1992) and Kornfeld et al. (1998). Twenty
lmoles of IDUA was phosphorylated by the soluble phospho-
transferase overnight at 37 °C under the conditions described
above. Phosphorylated cgl-IDUA was passed through Sephadex-
G-25, and the void volume was collected. The fraction was
adjusted to 600 lL with a buffer containing Tris–Maleate pH 6.7,
Triton X-100 0.5% and 500 ng uncovering enzyme. The reaction
mix was incubated at 37 °C, and at each time point, 30 lL was
taken for analysis. After stopping the reaction, the mixture was
passed through a 2-mL CM-cellulose chromatography column
pre-equilibrated with 50 mM dimethylglutarate (pH 6.0) and
eluted with 2 mL of the same buffer. The concentration of
[3H]-GlcNAc of the eluted fraction was determined by liquid
scintillation counting.
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